Want to see BGMS full AI Analyst Report?
BGMS Stock Chart & Stats
$1.45
--
Market closed
$1.45
--
Day’s Range― - ―
52-Week Range$0.57 - $19.87
Previous CloseN/A
VolumeN/A
Average Volume (3M)473.94K
Market Cap
$4.97M
Enterprise Value-$1.55M
Total Cash (Recent Filing)$3.34M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.77
Next Earnings
Aug 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield10.27%
Share Statistics
EPS (TTM)-4.40
Shares Outstanding5,519,456
10 Day Avg. Volume1,252,948
30 Day Avg. Volume473,939
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.47
Price to Sales (P/S)4.33
P/FCF Ratio-0.68
Enterprise Value/Market Cap-0.31
Enterprise Value/Revenue-1.02
Enterprise Value/Gross Profit-5.55
Enterprise Value/Ebitda0.43
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-268.8
Revenue Forecast (FY)$100.00K
Bulls Say, Bears Say
Bulls Say
Rapid Revenue GrowthSustained TTM revenue growth above 100% to $1.53M demonstrates clear commercial traction and demand for the company's offerings. Over the next several quarters this growth can materially improve operating leverage, help absorb fixed costs, and support margin expansion if product mix and gross margins hold.
Low Leverage / Improved EquityZero reported debt and a positive equity base (~$6.76M TTM) materially reduce solvency risk and preserve strategic optionality. A low-leverage position supports investment or M&A without heavy interest burden, extending the operating runway and financial flexibility over the next 2–6 months.
Strategic Acquisition DiversificationThe all-stock Future NRG acquisition targets regulated medical waste-to-energy and fire safety services, diversifying revenue into compliance-driven markets. Structurally, bundled environmental and safety offerings can create recurring revenue, deepen customer relationships, and stabilize demand in regulated niches.
Bears Say
Negative Operating Cash FlowPersistent negative operating and free cash flow (~-$1.8M TTM) means the business continues to consume cash despite revenue gains. This ongoing burn constrains reinvestment, raises the likelihood of further external financing, and creates a tangible runway risk unless cash generation improves materially.
Deep Operating & Net LossesVery large operating and net losses indicate the company remains unprofitable at current scale; modest gross margin (~18%) implies revenue must grow substantially to cover fixed costs. Structural unprofitability will delay break-even and limit returns unless margins improve or cost structure is rebalanced.
Reliance On Equity FinancingRecent use of equity raises (private placement ~ $794k) signals dependence on dilution to fund operations. Repeated reliance on equity funding increases dilution risk for shareholders and suggests the company may need further capital infusions until cash flow becomes self-sustaining.
Bio Green Med Solution News
BGMS FAQ
What was Bio Green Med Solution’s price range in the past 12 months?
Bio Green Med Solution lowest stock price was $0.57 and its highest was $19.87 in the past 12 months.
What is Bio Green Med Solution’s market cap?
Bio Green Med Solution’s market cap is $4.97M.
When is Bio Green Med Solution’s upcoming earnings report date?
Bio Green Med Solution’s upcoming earnings report date is Aug 12, 2026 which is in 30 days.
How were Bio Green Med Solution’s earnings last quarter?
Bio Green Med Solution released its earnings results on May 14, 2026. The company reported -$0.04 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.04.
Is Bio Green Med Solution overvalued?
According to Wall Street analysts Bio Green Med Solution’s price is currently Overvalued.
Does Bio Green Med Solution pay dividends?
Bio Green Med Solution pays a Notavailable dividend of $0.15 which represents an annual dividend yield of 10.27%. See more information on Bio Green Med Solution dividends here
What is Bio Green Med Solution’s EPS estimate?
Bio Green Med Solution’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bio Green Med Solution have?
Bio Green Med Solution has 5,519,456 shares outstanding.
What happened to Bio Green Med Solution’s price movement after its last earnings report?
Bio Green Med Solution reported an EPS of -$0.04 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -5.143%.
Which hedge fund is a major shareholder of Bio Green Med Solution?
Currently, no hedge funds are holding shares in BGMS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bio Green Med Solution
Bio Green Med Solution, Inc. (BGMS) operates as a multifaceted company, with active involvement in both the fire protection and biopharmaceutical industries. The organization recently broadened its capabilities by completing the acquisition of Fitters Sdn. Bhd., a Malaysian firm known for its fire safety products and services. BGMS is committed to driving progress in biopharmaceutical research and developing cutting-edge fire safety solutions, striving to deliver enduring value to its investors.
Technical Analysis
Biodexa Pharmaceuticals
―
―
Rein Therapeutics
―
Bluejay Diagnostics
―
Neuphoria Therapeutics
―
Ownership Overview
57.05% Insiders
0.03% Mutual Funds
<0.01% Other Institutional Investors
42.92% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---